The big difference here is that now we have the added problem of dealing with ACE2 bindings which affect human lungs/liver/heart/pancreas/etc.
This is a dangerous difference.
> SARS-CoV recognizes angiotensin-converting enzyme 2 (ACE2) as its receptor, whereas MERS-CoV recognizes dipeptidyl peptidase 4 (DPP4) as its receptor.
>>thowaw+(OP)
SARS-COV-1 also used ACE2 receptors. In fact your article specifically discusses that, and suggests there was potential to use SARS-COV-1 vaccine development to create SARS-COV-2 vaccines.